Over a decade ago, a disastrous trial killed research on a potential immunotherapy. Can a Regeneron bispecific revive it?
In 2006, a German biotech developed what they called a “superagonist” for CD28, a pocket on T cells that in theory could be used to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
